Table 2

Characteristics of melanoma brain metastases (MBMs) at commencement of ipilimumab–nivolumab (I–N)

First-line I–N (n=25)Second/third line I–N (n=30)Total (n=55)P value
Number of MBMs, median1210.146, M-W U=29.4
MBMs, no. (%)
 01 (4.0)2 (6.6)3 (5.5)
 115 (60.0)12 (40.0)27 (49.1)
 23 (12.0)3 (10.0)6 (10.9)
 32 (8.0)4 (13.3)6 (10.9)
 >34 (16.0)9 (30.0)13 (23.6)
Sum of MBM lesion diameters0.327, M-W
U=316.5
 Mean23.427.725.7
 Median1320.514
 Range0–1380–1080–138
 Symptomatic MBM*, no. (%)11 (44.0)8 (26.7)23 (38.3)0.256
 Leptomeningeal involvement, no. (%)3 (12.0)7 (23.3)10 (16.7)0.318
  • Number of MBMs refers to measurable target lesions by modified intracranial RECIST. The minimum size of measurable MBM was 5 mm on the longest axis. M-W denotes Mann-Whitney

  • *Denotes symptomatic at time of initial presentation with melanoma brain metastases (first-line I–N or symptomatic CNS progression prior to commencement of I–N (second/third Line I–N).

  • CNS, central nervous system; RECIST, Response Evaluation Criteria in Solid Tumours.